Active Not RecruitingNot applicableNCT03075072

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)

Checked against the public recordLast updated Oct 23, 2024 · Source: ClinicalTrials.gov

StatusActive Not Recruiting
PhaseNot applicable
U.S. locations2
SponsorDana-Farber Cancer Institute
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Dana-Farber Cancer Institute
Interventions being studied
Radiation: Whole brain radiation; Radiation: Stereotactic radiation (SRS)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Participants must have a biopsy proven solid malignancy with untreated (by radiation) intracranial lesions radiographically consistent with or pathologically proven to be brain metastases. Patients who have undergone prior systemic therapy are eligible * Five-twenty intracranial lesions must be present on MRI of the brain * Age 18-80 years at diagnosis of brain metastases * Karnofsky performance status of at least 70 Exclusion Criteria: * Participants who have undergone prior radiation for brain metastases. * Patients who have undergone resection of one or more brain metastases but who have not yet started adjuvant radiotherapy are eligible for the study * Participants who cannot undergo a brain MRI * Participants who cannot receive gadolinium (MRI contrast) * Participants with stage IV-V chronic kidney disease or end stage renal disease * Participants with widespread, definitive leptomeningeal disease * Participants with small cell lung cancer, lymphoma, or myeloma * Participants with a maximum tumor diameter exceeding 5 cm (if not resected)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Brigham and Women's HospitalBoston, Massachusetts
  • Dana Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 23, 2024. Always confirm current availability with the study team.

View original record ↗